Loading...

PHIO PHIO PHARMACEUTICALS CORP Product Launches 8-K Filing

PH P

PH

PHIO PHARMACEUTICALS CORP

(PHIO)

2024 8-K

Show Summary

Show Summary

Financial Statements

Clinical Trials

Accountant Change

Product Advancement

Financial Results

Board Appointment

Clinical Study Results

Clinical Trial Update

Financial Results

Clinical Data Presentation

Financial Results

Appointment of Chief Financ...

Compliance regained with re...

Entry into Material Definit...

Termination of Purchase Agr...

Reverse Stock Split

Annual Meeting Approval

Announcement of Safety Moni...

Purchase Agreement with Tri...

Financial Results

Financial Results

Agreement with Existing War...

Financial Results and Clini...

Clinical Trial Announcement

Financial Results

Annual Meeting and Incentiv...

Securities Purchase Agreements

Clinical Trial Initiation

FDA Clearance for Clinical ...

Financial Results

Amendment Filing

Securities Purchase Agreement

Poster Presentation Announc...

Financial Results

Closure of Silicon Valley Bank

Appointment of President an...

Compliance regained with re...

Reverse Stock Split

Special Meeting and Reverse...

External Links:

Phio Pharmaceuticals announced that a Safety Monitoring Committee approved moving to a higher dose in the Phase 1b trial of their lead compound PH-762 after reviewing safety data.

AI Assistant

PHIO PHARMACEUTICALS CORP

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.